Physician profile
David Rivera
NPI 1558417758
$5,310.88
in general payments reported to CMS, 2019-2025
24 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,421 · 2022: $1,951 · 2023: $1,556 · 2024: $259 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,939.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $819.40 | 2021-2023 | Breztri, Farxiga, Fasenra |
| Novo Nordisk INC | $561.00 | 2021-2023 | |
| Esperion Therapeutics, INC. | $539.41 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $397.79 | 2022-2023 | Jardiance |
| Abbvie INC. | $397.39 | 2021-2024 | |
| Amgen INC. | $342.02 | 2021-2025 | Tepezza, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $306.30 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $301.36 | 2021-2023 | Xarelto |
| Corcept Therapeutics | $243.01 | 2023 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $221.88 | 2021-2024 | Xifaxan |
| Mannkind Corporation | $213.54 | 2021 | |
| Horizon Therapeutics Plc | $152.56 | 2022 | |
| Csl Behring | $141.29 | 2023-2024 | Kcentra, Haegarda |
| Amarin Pharma, INC. | $127.17 | 2021 | |
| Viiv Healthcare Company | $125.00 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $121.69 | 2022 | |
| Exact Sciences Corporation | $91.24 | 2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $66.81 | 2021-2023 | Mounjaro |
| Teva Pharmaceuticals USA, INC. | $37.98 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $27.00 | 2023 | Rexulti |
| Nestle Healthcare Nutrition INC. | $25.24 | 2021 | |
| Solventum Corporation | $18.74 | 2024 | Bair Hugger |
| Scilex Pharmaceuticals INC. | $17.70 | 2021 | |
| Ardelyx, INC. | $15.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.